Cohance Lifesciences Ltd · NSE:COHANCE
Cohance Lifesciences — Suven Pharmaceuticals — Q4 FY2022 Earnings Presentation
24 slides from Cohance Lifesciences's earnings presentation, May 2022
Slide 1: Suven Pharma Earnings Presentation Q4 and Annual FY22
SUVEN PHARMA Earnings Presentation Q4 and Annual - FY22
Slide 2: Risk Statement
Risk Statement Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in
Slide 3: Table of Contents
4 14 Table of Operation & Financial Company Background Contents Performance Q4 and Annual FY22 3
Slide 4: Operation & Financial Performance Q4 FY22
Operation & Financial Performance Q4 FY22 4
Slide 5: Businesswise data
Businesswise data CDMO Pharma CDMO Spec Chem Formulations & Other 463.21 Ser vices 772.98 84.03 80.17 623.7 305.93 136.36 209.08 109.4 18.42 137.69 12.08 Q4FY21 Q4FY22 FY21 FY22 Q4FY21 Q4FY22 FY21 FY22 Q4FY21 Q4FY22 FY21 FY22 Note: Figures in Rs. Crore 5
Slide 6: Financial Snapshot
Financial Snapshot Q4FY22 FY22 Growth in Growth in Growth in Revenue EBITDA PAT 89.83% 201.02% 248.27% 47.27% 68.83% 80.82% 6
Slide 7: Key Ratios
Key Ratios Q4FY22 FY22 EBIT to EBITDA to PAT to Income Income Income 56.51% 58.60% 45.05% 48.32% 50.91% 37.01% 7
Slide 8: Financials Q4FY22
Financials Q4FY22 Revenue EBIDTA PAT EPS 4,983 2,245 8.8 2,920 4,001 1,953 1,370 RUPEES MN RUPEES MN RUPEES MN 5.4 RUPEES 2,592 970 665 2.5 Q4FY21 Q3FY22 Q4FY22 Q4FY21 Q3FY22 Q4FY22 Q4FY21 Q3FY22 Q4FY22 Q4FY21 Q3FY22 Q4FY22 8
Slide 9: Financials FY22
Financials FY22 Revenue EBIDTA PAT EPS 15,080 5,581 21.9 7,678 10,240 RUPEES MN RUPEES MN RUPEES MN 4,548 3,086 12.1 RUPEES FY21 FY22 FY21 FY22 FY21 FY22 FY21 FY22 9
Slide 10: Financials Q4FY22
Financials Q4FY22 EBITDA Margin (%) PAT Margin (%) 59% 49% 45% 37% 34% 25% Q4FY21 Q3FY22 Q4FY22 Q4FY21 Q3FY22 Q4FY22 10
Slide 11: Financials FY22
Financials FY22 EBITDA Margin (%) PAT Margin (%) 51% 44% 37% 30% FY21 FY22 FY21 FY22 11
Slide 12: Financial Table – Q4 FY22
Financial Table – Q4 FY22 Quarter ended Year ended 31-Mar-22 31-Dec-21 31-Mar-21 31-Mar-22 31-Mar-21 Revenue from operations 3,638.47 3,915.85 2,591.65 13,202.22 10,097.19 Other Income 1,343.96 92.74 32.98 1,877.88 142.37 Total Income 4,982.43 4,008.60 2,624.63 15,080.10 10,239.56 EBITDA 2,919.65 1,
Slide 13: Q4FY22 updates
Q4FY22 updates ñThe Board has declared 2nd interim Dividend of Rs.1.00 per equity share (100% of Face value of Rs.1.00 each) and one-time special dividend of Rs. 1.00 per equity share (100% of Face value of Rs.1.00), totaling to Rs. 2.00 per equity share (200% of Face value of Rs. 1.00 each) for the
Slide 14: Company Background
Company Background SUVEN 14 PHARMA
Slide 15: Business Model
Business Model Process Custom Research Synthesis Contract Development And Manufacturing Operations (CDMO) Formulation Clinical Development Supplies Mfg Analytical & & Packaging Services 15
Slide 16: Brief Profile
Brief Profile BUSINESS OVERVIEW o Integrated CDMO KEY STRENGTHS company with strong o Preferred global outsourcing FINANCIAL OVERVIEW capabilities right from partner with capabilities o Standalone Revenues, EBITDA and process research & across the entire CDMO Adj. PAT of Rs 4982 Mn, Rs 2920 Mn devel
Slide 17: Brief Overview
Brief Overview Suven is an integrated Contract Development and Manufacturing Operations company Suven provides services to leading Global Life Science and Fine Chemical majors including Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations. Since
Slide 18: NCE based CDMO
Our Focus NCE based A full-fledged bio- pharmaceutical solutions CDMO provider for global pharmaceutical companies 18 18
Slide 19: Financial Approach
Financial Approach Consistently Low dividend debt paying Shareholder Prudent value creation utilisation of focus cash flows 19
Slide 20: Business Drivers
Business Drivers Industry Relationship An integrated research service provider with Leveraging on unmatched capabilities research capabilities Present across the to delivering NCE entire CDMO value research chain – State of the art intermediates & facilities located APIs across India and US 20
Slide 21: Business Drivers
Business Drivers Execution Capabilities Over 90% of Working with revenues from innovator companies regulated in developed markets markets having stringent regulations – Long term reflection of our commercial supply research skills Repeat business with the launch of owing to long product by global st
Slide 22: Multi Location Facilities
Multi Location Facilities o o 300 CM reactors (93) 500L to 10 KL GL/SS o GMP Intermediates Vizag, Andhra Pashamylaram, Telangana, India Banjara Hills, Hyderabad, India Suryapet, Telangana, India Pradesh, India API & Formulation Facility Corporate Office Intermediate Mfg. Facility o 307 KL reactor vo
Slide 23: Contact
Contact For queries and requests, please contact: Suven Pharmaceuticals Ltd Suven Pharmaceuticals Ltd Email: info@suvenpharm.com For more info: www.suvenpharm.com # 8-2-334, SDE Serene Chambers, 3rd Floor, Road No. 5, Avenue - 7, Banjara Hills, Hyderabad-500 034, Telangana, INDIA. Gavin Desa / Risha
Slide 24: Thank You
Thank You
Suven Pharmaceuticals — Q4 FY2022 Earnings Presentation on 6ix